EQRX — EQRx Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
Brief: Revolution Medicines Inc Says Will Acquire EQRx In An All-Stock Transaction
U.S. RESEARCH ROUNDUP- Cigna Group, McKesson, Zscaler
Brief: EQRx posts Q1 EPS USD -0.17
Brief: EQRx Says Jami Rubin Will Step Down As Chief Financial Officer
Brief: Eqrx Inc Files For Mixed Shelf Of Up To $300 Million – SEC Filing
Brief: Eqrx Inc Files Prospectus Relates To Issuance By Co Of Of Up To 19.7 Million Shares Of Common Stock - SEC Filing
Brief: EQRx Reports Fourth Quarter And Full Year 2022 Financial Results
Brief: EQRx Posts Q4 Loss Per Share Of $0.05
Brief: Softbank Group Corp Is Determined To Sell Some Or All Holdings Of Shares Of EQRX In Open Market
Brief: EQRx Inc Expects To Report That It Had About $1.4 Bln Of Cash, Cash Equivalents And Short-Term Investments As Of Dec 31, 2022
Brief: Eqrx Announces Acceptance Of Marketing Authorization Application By The Uk’S Medicines And Healthcare Products Regulatory Agency For Sugemalimab In Metastatic Non-Small Cell Lung Cancer
Brief: Eqrx Announces Acceptance Of Marketing Authorization Application By The European Medicines Agency For Aumolertinib In Egfr-Mutated Non-Small Cell Lung Cancer
U.S. RESEARCH ROUNDUP-Expensify, NVIDIA, Signature Bank
EQRx Inc reports results for the quarter ended in September - Earnings Summary
Brief: EQRx Reports Q3 Loss Of $0.18 Per Share
EQRx Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: EQRx reports Q2 results
Brief: EQRx Announces Acceptance Of Marketing Authorization Application By The UK'S Medicines And Healthcare Products Regulatory Agency For Aumolertinib In EGFR-Mutated Non-Small Cell Lung Cancer
Brief: Eqrx Announces New Data For Lead Oncology Programs In Non-Small Cell Lung Cancer And Rare Form Of Non-Hodgkin Lymphoma At Asco 2022